DGAP-News: MorphoSys and I-Mab Biopharma Announce Initiation of Pivotal Phase 2 Study of TJ202/MOR202 for Multiple Myeloma

DGAP-News: MorphoSys AG / Key word(s): Study MorphoSys and I-Mab Biopharma Announce Initiation of Pivotal Phase 2 Study of TJ202/MOR202 for Multiple Myeloma (news with additional features) 19.03.2019 / 22:01 The issuer is solely responsible for the content of this announcement. Planegg/Munich, Germany, and Shanghai, China, March 19, 2019   MorphoSys and I-Mab Biopharma Announce Initiation of Pivotal Phase 2 Study of TJ202/MOR202 for Multiple Myeloma   MorphoSys AG (FSE: MOR; Prime Standard Segment, MDAX & TecDAX; NASDAQ: MOR) and I-Mab Biopharma (I-Mab), a China-based clinical stage biopharmaceutical company exclusively focused on the development of innovative biologics in immuno-oncology and ...

Gepostet in der Kategorie Wirtschaft (Anzahl der ansichten:) 6

Ähnlich Nachrichten